Actavis (NYSE: ACT) is a unique specialty pharmaceutical company focused on developing, manufacturing and commercializing high quality affordable generic and innovative branded pharmaceutical products for patients around the world.

The Company has global headquarters in Dublin, Ireland and U.S. Administrative Headquarters in Parsippany, New Jersey, USA.

Highlights
Actavis markets a broad portfolio of branded and generic pharmaceuticals and develops innovative medicines for patients suffering from diseases principally in the central nervous system, gastroenterology, women’s health, urology, cardiovascular, respiratory and anti-infective therapeutic categories.
Actavis markets approximately 1000 generic, branded generic, established brands and Over-the-Counter (OTC) pharmaceutical products globally through operations in more than 60 countries.
The Company is an industry leader in product research and development, with one of the broadest brand development pipelines in the pharmaceutical industry, and a leading position in the submission of generic product applications. Actavis has commercial operations in more than 60 countries and operates more than 30 manufacturing and distribution facilities around the world.

Publications 63 show all

  • 6
    Pulmonary Disease, Chronic Obstructive/drug therapy
  • 4
    Cyclopropanes/pharmacokinetics
  • 3
    Aminopyridines/therapeutic use
  • 3
    Anxiety Disorders/drug therapy
  • 3
    Benzamides/therapeutic use
  • 2
    Alzheimer Disease/drug therapy
  • 2
    Aminopyridines/economics
  • 2
    Anti-Bacterial Agents/administration & dosage
  • 2
    Anti-Bacterial Agents/adverse effects
  • 2
    Anti-Bacterial Agents/pharmacokinetics

Patents 17,051show all

8,425Applications6,410Issued

Clinical Trials 809show all

187Phase 3151Phase 4124Phase 2107Phase 178N/A30Other

SEC Filings show all


128
8-K

15
10-Q

5
10-K

Contact Information

Dublin
Ireland